Skip to main content

Table 2 Premorbid immunosuppression, chemotherapy and corticosteroid exposure among 297 patients with positive PCR for P. jirovecii

From: Epidemiological and clinical characteristics of immunocompromised patients infected with Pneumocystis jirovecii in a twelve-year retrospective study from Norway

Immunosuppression/chemotherapy regimens at presentation, n (%)
 Chemotherapy for hematological malignancy with adjuvant corticosteroids 67 (22.6)
 Corticosteroids in monotherapy 44 (14.8)
 Graft rejection prophylaxis after solid organ transplantation 36 (12.1)
 Chemotherapy for solid malignancy with adjuvant corticosteroids 33 (11.1)
 DMARDs with adjuvant corticosteroids 22 (7.4)
 Chemotherapy for solid malignancy 16 (5.4)
 Chemotherapy for hematological malignancy 12 (4.0)
 Corticosteroids and other immunosuppressantsa 8 (2.7)
 DMARDs in monotherapy 5 (1.7)
 Prophylaxis or treatment for GVHD after allogenic stem cell transplantation 3 (1.0)
 Other combinationsb 2 (0.7)
 None 49 (16.5)
Systemic corticosteroid exposure last 60 days prior to presentation, n (%)
 Daily 125 (42.1)
 Intermittent 91 (30.6)
 No exposure to systemic corticosteroids 79 (26.6)
 No information 2 (0.7)
Corticosteroid daily dosage in mg methylprednisolone at presentation, n = 292
 Median the day of P. jirovecii detection (q1-q3), n = 146 8 (4–20)
 Minimum, maximum 0,120
Indications for corticosteroid administration among exposedc, n (%)
 Immunosuppression for immunological disorders or graft rejection prophylaxis 99 (46.3)
 Chemotherapy 75 (35.0)
 Anti-emesis and other oncological indicationsd 51 (23.8)
 Peritumoral oedema in primary and secondary intracranial tumors 16 (7.5)
 Hematological and solid malignancies complicated by AIHA or ITP 9 (4.2)
  1. Abbreviations: AIHA autoimmune hemolytic anemia, DMARDs disease-modifying anti-rheumatic drugs, GVHD graft-versus-host disease, ITP immune thrombocytopenic purpura
  2. aOther immunosuppressants include mycophenolate, azathioprine, cyclophosphamide, calcineurin- and mTOR-inhibitors, cyclosporine and hydroxychloroquine
  3. bOther combinations of immunosuppressive regimens include one patient receiving graft rejection prophylaxis for solid organ transplantation in combination with chemotherapy for hematological malignancy with adjuvant corticosteroids and one patient receiving azathioprine for vasculitis, respectively
  4. c214 patients (72.1%) had known exposure to systemic corticosteroids last 60 days prior to presentation, and proportions are expressed with 214 as denominator. In some cases, corticosteroids were prescribed for more than one indication
  5. dOther oncological indications include peritumoral oedema for patients with extracranial tumors, corticosteroids in combination with radiotherapy, vena cava superior syndrome, medulla compression etc.